Business Wire

TREKSTOR

28.1.2021 11:45:02 CET | Business Wire | Press release

Share
TREKSTOR Donates 100.000 FFP2 Respirators to Tafel Deutschland e.V.

Today the TREKSTOR GmbH, the manufacturer behind the blnk branded healthcare products, completed delivery of 100.000 FFP2 class respirators to the Tafel Deutschland. This is a reaction to the increased demand for certified PPE products created by both decisions of the federal government as well as the FFP2 mandate active in the state of Bavaria.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005522/en/

„As a German company, which mainly exists today due to the sales of entry-level PCs and tablets to price-sensitive customers in the past, we are aware of our responsibility to our fellow citizens“ , Shimon Szmigiel, CEO of TREKSTOR, explains. „Many of them are lagging the financial prowess to purchase high quality protective equipment, a state that is worsened by lay-offs and short-time work arrangements.”

Therefore, TREKSTOR decided on short notice to donate 50.000 packs containing 2 pcs of its own blnk brand model BL-03N FFP2 respirators, which are normally sold to government, hospital and care facilities. As do all FFP2 respirators, it filters ≥94% of particles, in the COVID-19 relevant comparison with NaCL, the masks even performed above the 99% mark.

„The selection of Tafel Deutschland as our partner was very easy“ , adds Shimon Szmigiel. This is due to existing infrastructure and experience when it comes to distributing food, which makes the Tafel to a unique distribution network. Based on the agreement, the respirators were delivery to a central warehouse in Nurnberg and will from there be distributed to the 168 locations in Bavaria according to demand.

Jochen Brühl, Chairman of Tafel Deutschland: „We are delighted for this wonderful support. People in poverty are especially affected by this crisis. As important as the mask mandate is, it is a financial burden for poor people. Around 1.6 million people rely on our food banks, among them 430.000 retirees and up to 500.000 children and youths. The donation by TREKSTOR helps them to protect themselves while also relieving some of the financial pressure. For that, we are very thankful.“

TREKSTOR is aware, that this donation is literally only a drop in the ocean, which is why Shimon Szmigiel appeals to all other businesses: “If you are active in the same areas we are – or if you are not, take heart, temporarily forget about profit, and do something good.”

About TREKSTOR / blnk Healthcare
TREKSTOR, known as one of Europe’s leading consumer electronics manufacturers based in Bensheim, Germany, has been active in the healthcare space with its brand blnk starting March 2020, helping to stop the spread of the virus via face masks, disinfectants and other protective equipment. The company is selling equally to government institutions and the army alongside direct sales to care facilities, hospitals, pharmacies, and end-consumers.

About Tafel Deutschland e.V.
The 950 charitable food banks in Germany collect impeccable surplus food from retailers and manufacturers and distribute it regularly to more than 1.6 million poor people across the country. In doing so, they create a balance between waste and poverty. With around 60,000 volunteers who are involved in the food banks, the food banks are one of the largest socio-ecological movements in Germany. The food banks are organized in the umbrella organization Tafel Deutschland e. V.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye